This document provides a material safety data sheet for bupropion hydrochloride (Bupropion HCl). It summarizes the chemical and physical properties of Bupropion HCl, potential health effects, guidelines for safe handling and storage, exposure controls, and disposal considerations. The document contains information on the product name and manufacturer contact information in section 1, composition in section 2, hazards identification in section 3, first aid measures in section 4, fire fighting measures in section 5, accidental release measures in section 6, handling and storage in section 7, exposure controls and personal protection in section 8, physical properties in section 9, stability in section 10, toxicological information in section 11, ecological information in section 12,
WestMoonint manufactures high-quality Chlorosulfonated-Polyethylene, which includes CSM-40 and CSM-45 grades, which are similar with DuPont’s Hypalon-40 and Hypalon-45 grades in terms of physical properties and performance.
Prakash Chemicals International providing best quality sles 70 at competitive prices. We are well-known for superior quality. For more information, please visit our website.
Product Identifier: Poly 1511 Liquid Plastic Part B
Poly 1512 Liquid Plastic Part B
Poly 1512X Liquid Plastic Part B
Product Code(s): 1511B, 1512B, 1512XB
Use: Component for Liquid Polyurethane Casting
Plastic. For Industrial/Professional use only.
Manufacturer: Polytek Development Corp.
55 Hilton St., Easton, PA 18042
Phone Number: 610-559-8620 (8 a.m. to 6:30 p.m. EST)
Emergency Phone: CHEMTREC 800-424-9300 or
+1 (703) 527-3887
E-mail: sds@polytek.com
WestMoonint manufactures high-quality Chlorosulfonated-Polyethylene, which includes CSM-40 and CSM-45 grades, which are similar with DuPont’s Hypalon-40 and Hypalon-45 grades in terms of physical properties and performance.
Prakash Chemicals International providing best quality sles 70 at competitive prices. We are well-known for superior quality. For more information, please visit our website.
Product Identifier: Poly 1511 Liquid Plastic Part B
Poly 1512 Liquid Plastic Part B
Poly 1512X Liquid Plastic Part B
Product Code(s): 1511B, 1512B, 1512XB
Use: Component for Liquid Polyurethane Casting
Plastic. For Industrial/Professional use only.
Manufacturer: Polytek Development Corp.
55 Hilton St., Easton, PA 18042
Phone Number: 610-559-8620 (8 a.m. to 6:30 p.m. EST)
Emergency Phone: CHEMTREC 800-424-9300 or
+1 (703) 527-3887
E-mail: sds@polytek.com
Antioxidant 1010 irganox 1010 6683 19-8 msds, Our products are organic pigments, antioxidants, uv absorber, light stabilizers, optical brighteners. Also are agent of Addivant and Xrite in China, website:https://www.additivesforpolymer.com email:info@additivesforpolymer.com
Optical brightener er i 13001-39-3 msds, Our products are organic pigments, antioxidants, uv absorber, light stabilizers, optical brighteners. Also are agent of Addivant and Xrite in China, website:https://www.additivesforpolymer.com email:info@additivesforpolymer.com
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
1. p. 1
Bupropion HCl (Cas 31677-93-7) MSDS
1
SHANDONG OCTAGON CHEMICALS LIMITED
TEL:0086-0535-6715688 Email: sales@octagonchem.com
Address: Rm 528, Building 2, No. 300-2, Changjiang Rd, YEDA, YanTai City, ShanDong
Province, China
Bupropion HCl MSDS
Section 1: Chemical Product and Company Identification
Product Name: Bupropion HCl
CAS#: 31677-93-7
TSCA: TSCA 8(b) inventory:Bupropion HCl
CI#: Not Available
Synonym: Bupropion Hydrochloride powder, 31677-93-7
Chemical Formula: C13H19Cl2NO
Contact Information:
SHANDONG OCTAGON
CHEMICALS LIMITED
Add.: Rm 528, Building 2, No. 300-2, Changjiang Rd, YEDA,
YanTai City, ShanDong Province, China
16th
CHEMTREC (24HR Emergency Telephone), call:
+ 86-13071891945
International CHEMTREC, call: + 86-13071891945
For non-emergency assistance, call: + 86-13071891945
Section 2: Composition and Information on Ingredients
Composition:
Name CAS # % by Weight
Bupropion HCl 31677-93-7 99%
Toxicological Data on Ingredients: Bupropion HCl: Rat ORAL (LD50): NA
Section 3: Hazards Identification
Potential Acute Health Effects:
Very hazardous in case of eye contact (irritant), of ingestion. Hazardous in case of skin contact (irritant), of inhalation. Slightly
hazardous in case of skin contact (permeator). Inflammation of the eye is characterized by redness, watering, and itching.
Potential Chronic Health Effects:
CARCINOGENIC EFFECTS: Not Available MUTAGENIC EFFECTS: Not Available TERATOGENIC EFFECTS: Not Available
DEVELOPMENTAL TOXICITY: Not Available The substance is toxic to lungs, the nervous system, mucous membranes.
Repeated or prolonged exposure to the substance can produce target organs damage.
Section 4: First Aid Measures
Eye Contact:
Check for and remove any contact lenses. In case of contact, immediately flush eyes with plenty of water for at least 15
minutes. Cold water may be used. WARM water MUST be used. Get medical attention immediately.
2. p. 2
Bupropion HCl (Cas 31677-93-7) MSDS
2
Skin Contact:
In case of contact, immediately flush skin with plenty of water. Cover the irritated skin with an emollient. Remove contaminated
clothing and shoes. Wash clothing before reuse. Thoroughly clean shoes before reuse. Get medical attention.
Serious Skin Contact:
Wash with a disinfectant soap and cover the contaminated skin with an anti-bacterial cream. Seek immediate medical
attention.
Inhalation:
If inhaled, remove to fresh air. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical
attention.
Serious Inhalation: Not Available
Ingestion:
Do NOT induce vomiting unless directed to do so by medical personnel. Never give anything by mouth to an unconscious
person. If large quantities of this material are swallowed, call a physician immediately. Loosen tight clothing such as a collar,
tie, belt or waistband.
Serious Ingestion: Not Available
Section 5: Fire and Explosion Data
Flammability of the Product: Non flammable.
Auto-Ignition Temperature: Not Available
Flash Points: No data
Flammable Limits: Not available.
Products of Combustion: These products are carbon oxides (CO, CO2), nitrogen oxides (NO, NO2...), sulfur oxides (SO2,
SO3...).
Fire Hazards in Presence of Various Substances: Not Available
Explosion Hazards in Presence of Various Substances:
Risks of explosion of the product in presence of mechanical impact: Not Available
Risks of explosion of the product in presence of static discharge: Not Available
Fire Fighting Media and Instructions:
SMALL FIRE: Use DRY chemical powder. LARGE FIRE: Use water spray, fog or foam. Do not use water jet.
Special Remarks on Fire Hazards: Not Available
Special Remarks on Explosion Hazards: Not Available
Section 6: Accidental Release Measures
Small Spill:
Use appropriate tools to put the spilled solid in a convenient waste disposal container. Finish cleaning by spreading water on
the contaminated surface and dispose of according to local and regional authority requirements.
Large Spill:
Use a shovel to put the material into a convenient waste disposal container. Finish cleaning by spreading water on the
contaminated surface and allow to evacuate through the sanitary system.
Section 7: Handling and Storage
Precautions:
3. p. 3
Bupropion HCl (Cas 31677-93-7) MSDS
3
Keep away from heat. Keep away from sources of ignition. Empty containers pose a fire risk, evaporate the residue under a
fume hood. Ground all equipment containing material. Do not ingest. Do not breathe dust. In case of insufficient ventilation,
wear suitable respiratory equipment. If ingested, seek medical advice immediately and show the container or the label. Avoid
contact with skin and eyes.
Storage: Keep container tightly closed. Keep container in a cool, well-ventilated area.
Section 8: Exposure Controls/Personal Protection
Engineering Controls:
Use process enclosures, local exhaust ventilation, or other engineering controls to keep airborne levels below recommended
exposure limits. If user operations generate dust, fume or mist, use ventilation to keep exposure to airborne contaminants
below the exposure limit.
Personal Protection:
Splash goggles. Lab coat. Dust respirator. Be sure to use an approved/certified respirator or equivalent. Gloves.
Personal Protection in Case of a Large Spill:
Splash goggles. Full suit. Dust respirator. Boots. Gloves. A self contained breathing apparatus should be used to avoid
inhalation of the product. Suggested protective clothing might not be sufficient; consult a specialist BEFORE handling this
product.
Exposure Limits: Not Available
Section 9: Physical and Chemical Properties
Physical state and appearance: white powder
Molecular Weight: 276.2 g/mol
Color: white
Boiling Point: NA
Melting Point: NA
Solubility: Insoluble in methanol, ethanol.
Section 10: Stability and Reactivity Data
Stability: The product is stable.
Instability Temperature: Not Available
Conditions of Instability: Not Available
Incompatibility with various substances: Not Available
Corrosivity: Non-corrosive in presence of glass.
Special Remarks on Reactivity: Not Available
Special Remarks on Corrosivity: Not Available
Polymerization: Will not occur.
Section 11: Toxicological Information
Routes of Entry: Eye contact. Inhalation. Ingestion.
Toxicity to Animals: Acute oral toxicity (Rat Oral LD50):NA
Chronic Effects on Humans: Causes damage to the following organs: lungs, the nervous system, mucous membranes.
4. p. 4
Bupropion HCl (Cas 31677-93-7) MSDS
4
Other Toxic Effects on Humans:
Very hazardous in case of Ingestion. Hazardous in case of of inhalation. Slightly hazardous in case of skin contact.
Special Remarks on Toxicity to Animals: Not Available
Special Remarks on Chronic Effects on Humans: Not Available
Special Remarks on other Toxic Effects on Humans: Not Available
Section 12: Ecological Information
Eco-toxicity: Not Available
BOD5 and COD: Not Available
Products of Bio-degradation:
Possibly hazardous short term degradation products are not likely. However, long term degradation products may arise.
Toxicity of the Products of Bio-degradation: Not Available.
Special Remarks on the Products of Biodegradation: The substance is possibly harmful for the aquatic environment.
Section 13: Disposal Considerations
Waste Disposal:
Dispose of any cleanup materials and waste residue according to applicable laws or regulations.
Section 14: Transport Information
DOT Classification: Not a DOT controlled material (United States).
Identification: Not available.
Special Provisions for Transport: Not available.
Section 15: Other Regulatory Information
Federal and State Regulations: TSCA 8(b) inventory: Bupropion HCl: OSHA: Hazardous by definition of Hazard Communication
Standard (29 CFR 1910.1200).
Other Classifications:
WHMIS (Canada): CLASS D-2A: Material causing other toxic effects.
DSCL (EEC): R22- Harmful if swallowed. R38- Irritating to skin. R41- Risk of serious damage to eyes.
HMIS (U.S.A.): Health
Hazard: 2
Fire Hazard: 1
Reactivity: 0
Personal Protection: E
National Fire Protection Association (U.S.A.):
Health: 2
Flammability: 1
Reactivity: 0
5. p. 5
Bupropion HCl (Cas 31677-93-7) MSDS
5
Specific hazard:0
Protective Equipment:
Gloves. Lab coat. Dust respirator. Be sure to use an approved/certified respirator or equivalent. Wear appropriate respirator
when ventilation is inadequate. Splash goggles.
Section 16: Other Information
References: Not Available
Other Special Considerations: Not Available
Disclaimer:
The information above is believed to be as accurate as possible and represents the best information currently available to us.
However, we make no warranty of merchantability or any other warranty, express or implied, with respect to such information,
and we assume no liability resulting from its use. Users should make their own investigations to determine the suitability of the
information for their particular purposes. In no event shall SHANDONG OCTAGON CHEMICALS LIMITED be liable for any
claims, losses, or damages of any third party or for lost profits or any special, indirect, incidental, consequential or exemplary
damages, howsoever arising, even if Octagon Chemicals Limited has been advised of the possibility of such damages.